Cancer Research UK and Cancer Research Technology (CRT) will commence the phase I clinical trial of GlaxoSmithKline's (GSK) anti-cancer drug 1070916A, an aurora kinase inhibitor.
The joint initiative hopes that inhibiting the aurora kinase enzymes will possibly disrupt cellular division and therefore restrict tumour growth.
The phase I trial will be conducted on about 30–40 patients suffering from solid tumours who had gone through all the treatments available at present.
Following the success of the trial, Cancer Research UK will have the option to carry out the phase II trial.
Cancer Research UK will sponsor the trial at the Institute of Oncology at St James's University Hospital in Leeds and Barts and The London's Experimental Cancer Medicine Centre.
Cancer Research UK will support the study through early clinical development. GSK will have an option for further development and commercialisation of the molecule in exchange for future payments to Cancer Research UK. CRT will have the rights to the molecule to secure an alternative partner, if GSK does not wish to take the programme ahead.